Abstract
Background: Margin-negative pancreatectomy provides only chance to cure pancreatic cancer. However, borderline resectable pancreatic cancer (BRPCa) has the risk of incomplete palliative resection. Materials and Methods: We retrospectively reviewed 32 patients with BRPCa who underwent a pancreatectomy following preoperative chemoradiation therapy (CCRT (+)/Px group) and compared these patients with those with resectable pancreatic cancer (RPCa) who underwent pancreatectomy without preoperative CCRT (CCRT (-)/Px group, n = 104). Results: Eighteen patients (56. 2%) showed more than 50% significant pathological response to CCRT. The degree of pathological responses showed a positive relationship between final pT stage (p = 0. 075). More frequent vascular resection (p < 0. 001), transfusion (p = 0. 076), and longer operation time were observed in the CCRT(+)/Px group. However, similar R0 resection rates (p = 0. 272), lower pT stage (p < 0. 001), smaller number of metastastic lymph nodes (p = 0. 002), and lower incidence of lymph node metastasis (p = 0. 032) were noted in the CCRT(+)/Px group. The overall disease-specific survival were similar (median survival, 30. 5 months (95% CI; 23. 6-37. 4) vs. 26. 3 months (95% CI; 15. 9-36. 7), p = 0. 709), and no statistical differences in cancer recurrence risks were noted between the two groups (p = 0. 505). Conclusion: Pancreatectomy following preoperative neoadjuvant CCRT can be a potential strategy for margin-negative resection in BRPCa patients.
| Original language | English |
|---|---|
| Pages (from-to) | 509-517 |
| Number of pages | 9 |
| Journal | Journal of Gastrointestinal Surgery |
| Volume | 16 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2012 Mar 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Surgery
- Gastroenterology
Cite this
}
Potential Contribution of Preoperative Neoadjuvant Concurrent Chemoradiation Therapy on Margin-Negative Resection in Borderline Resectable Pancreatic Cancer. / Kang, ChangMoo; Chung, Yong Eun; Park, Jeong Youp; Seong, Jinsil; Hwang, Ho Kyoung; Choi, Hye Jin; Kim, Hyunki; Song, Si Young; Lee, Woo Jung.
In: Journal of Gastrointestinal Surgery, Vol. 16, No. 3, 01.03.2012, p. 509-517.Research output: Contribution to journal › Article
TY - JOUR
T1 - Potential Contribution of Preoperative Neoadjuvant Concurrent Chemoradiation Therapy on Margin-Negative Resection in Borderline Resectable Pancreatic Cancer
AU - Kang, ChangMoo
AU - Chung, Yong Eun
AU - Park, Jeong Youp
AU - Seong, Jinsil
AU - Hwang, Ho Kyoung
AU - Choi, Hye Jin
AU - Kim, Hyunki
AU - Song, Si Young
AU - Lee, Woo Jung
PY - 2012/3/1
Y1 - 2012/3/1
N2 - Background: Margin-negative pancreatectomy provides only chance to cure pancreatic cancer. However, borderline resectable pancreatic cancer (BRPCa) has the risk of incomplete palliative resection. Materials and Methods: We retrospectively reviewed 32 patients with BRPCa who underwent a pancreatectomy following preoperative chemoradiation therapy (CCRT (+)/Px group) and compared these patients with those with resectable pancreatic cancer (RPCa) who underwent pancreatectomy without preoperative CCRT (CCRT (-)/Px group, n = 104). Results: Eighteen patients (56. 2%) showed more than 50% significant pathological response to CCRT. The degree of pathological responses showed a positive relationship between final pT stage (p = 0. 075). More frequent vascular resection (p < 0. 001), transfusion (p = 0. 076), and longer operation time were observed in the CCRT(+)/Px group. However, similar R0 resection rates (p = 0. 272), lower pT stage (p < 0. 001), smaller number of metastastic lymph nodes (p = 0. 002), and lower incidence of lymph node metastasis (p = 0. 032) were noted in the CCRT(+)/Px group. The overall disease-specific survival were similar (median survival, 30. 5 months (95% CI; 23. 6-37. 4) vs. 26. 3 months (95% CI; 15. 9-36. 7), p = 0. 709), and no statistical differences in cancer recurrence risks were noted between the two groups (p = 0. 505). Conclusion: Pancreatectomy following preoperative neoadjuvant CCRT can be a potential strategy for margin-negative resection in BRPCa patients.
AB - Background: Margin-negative pancreatectomy provides only chance to cure pancreatic cancer. However, borderline resectable pancreatic cancer (BRPCa) has the risk of incomplete palliative resection. Materials and Methods: We retrospectively reviewed 32 patients with BRPCa who underwent a pancreatectomy following preoperative chemoradiation therapy (CCRT (+)/Px group) and compared these patients with those with resectable pancreatic cancer (RPCa) who underwent pancreatectomy without preoperative CCRT (CCRT (-)/Px group, n = 104). Results: Eighteen patients (56. 2%) showed more than 50% significant pathological response to CCRT. The degree of pathological responses showed a positive relationship between final pT stage (p = 0. 075). More frequent vascular resection (p < 0. 001), transfusion (p = 0. 076), and longer operation time were observed in the CCRT(+)/Px group. However, similar R0 resection rates (p = 0. 272), lower pT stage (p < 0. 001), smaller number of metastastic lymph nodes (p = 0. 002), and lower incidence of lymph node metastasis (p = 0. 032) were noted in the CCRT(+)/Px group. The overall disease-specific survival were similar (median survival, 30. 5 months (95% CI; 23. 6-37. 4) vs. 26. 3 months (95% CI; 15. 9-36. 7), p = 0. 709), and no statistical differences in cancer recurrence risks were noted between the two groups (p = 0. 505). Conclusion: Pancreatectomy following preoperative neoadjuvant CCRT can be a potential strategy for margin-negative resection in BRPCa patients.
UR - http://www.scopus.com/inward/record.url?scp=84856700060&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856700060&partnerID=8YFLogxK
U2 - 10.1007/s11605-011-1784-3
DO - 10.1007/s11605-011-1784-3
M3 - Article
VL - 16
SP - 509
EP - 517
JO - Journal of Gastrointestinal Surgery
JF - Journal of Gastrointestinal Surgery
SN - 1091-255X
IS - 3
ER -